Olartan-Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan Medoxomil, the active ingredient in Olartan-Plus, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It treats hypertension in adult patients and helps lower cardiovascular risk.

GNH USA supplies Olartan-Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olartan-Plus, an ARB‑thiazide combination, is used to manage elevated blood pressure within the hypertension therapeutic area.

- Hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular control.

Adverse reactions may occur with Olartan-Plus and are categorized by frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angioedema - Severe electrolyte imbalance (e.g., hyponatremia) - Allergic skin reactions (e.g., rash, Stevens‑Johnson syndrome)

Patients should be aware of specific safety considerations before using Olartan-Plus.

- Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Renal impairment: monitor kidney function and adjust therapy as needed. - Electrolyte balance: check serum potassium and sodium regularly. - Concomitant diuretics: assess for additive hypotensive effects. - Gout: may increase serum uric acid; monitor in susceptible individuals. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Olartan-Plus may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs) – risk of severe hypotension and renal failure. - Potassium‑sparing diuretics or supplements – risk of hyperkalemia. - Lithium – increased lithium levels, potential toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs – may reduce antihypertensive effect and impair renal function. - Antidiabetic agents – may enhance hypoglycemic effect. - CYP450 inhibitors (e.g., ketoconazole) – may increase olmesartan levels. - Loop diuretics – additive diuretic effect, monitor electrolytes.